Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 35

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 35
---
Settlement for sales of common shares
will occur on the first business day or such shorter settlement cycle as may be in effect under the Exchange Act from time to time, following
the date on which any sales are made, or on some other date that is agreed upon by us and Wainwright in connection with a particular transaction,
in return for payment of the net proceeds to us. Sales of our common shares as contemplated in this prospectus supplement and accompanying
prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Wainwright may agree
upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.

We will pay Wainwright a cash commission
equal to 3.0% of the gross sales price per common shares issued by us and sold by Wainwright under the Sales Agreement. Because there
is no minimum offering amount required as a condition to this offering, the actual total offering amount, sales commissions and net proceeds
to us, if any, are not determinable at this time. Pursuant to the terms of the Sales Agreement, we have agreed to pay Wainwright a fee
not to exceed $50,000 for the reasonable fees and expenses of its legal counsel (excluding any periodic due diligence fees) incurred in
connection with entering into the transactions contemplated by the Sales Agreement, which was paid at the commencement of this offering.
Additionally, pursuant to the terms of the Sales Agreement, we have also agreed to reimburse Wainwright (i) $5,000 per due diligence update
session conducted in connection with each such date we file our Annual Report on Form 10-K and (ii) $2,500 per due diligence update session
in connection with each such date we file our Quarterly Reports on Form 10-Q. We estimate that the total expenses of the offering payable
by us, excluding commissions payable to Wainwright under the Sales Agreement, will be approximately $300,000, assuming we sell the entire
amount offered pursuant to this prospectus supplement and the accompanying prospectus. We will disclose in our Annual Reports on Form
10-K and Quarterly Reports on Form 10-Q, as applicable, the number of our common shares sold through Wainwright under the Sales Agreement,
the net proceeds to us and the compensation paid by us with respect to sales under the Sales Agreement during the relevant quarter.

In connection with the sales of common
shares on our behalf, Wainwright will be